The gene editor Intellia was first to market with a therapeutic candidate. Christoph Behrens and Lukas Bischoff at Meissner trace how it took its IP from Nobel to Nasdaq, creating a clear path of licences to access science and know-how

Christoph Behrens and Lukas Bischoff

In 2021, Intellia Therapeutics announced a proof of concept for precisely editing the target of a genetic disease. It was the first time that any such clinical human data had been published. In this case, it covers a rare liver disease. Unthinkable ten years ago, it now opens the way for other therapeutic treatments, including cancer.